Immunomedics (NASDAQ: IMMU) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Immunomedics to related businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, risk, earnings and dividends.
Institutional and Insider Ownership
76.3% of Immunomedics shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.6% of Immunomedics shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Immunomedics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunomedics||$3.09 million||-$153.20 million||-7.02|
|Immunomedics Competitors||$217.40 million||-$39.57 million||-63.63|
Immunomedics’ rivals have higher revenue and earnings than Immunomedics. Immunomedics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and target prices for Immunomedics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunomedics presently has a consensus price target of $15.50, suggesting a potential downside of 1.40%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.73%. Given Immunomedics’ rivals higher probable upside, analysts plainly believe Immunomedics has less favorable growth aspects than its rivals.
This table compares Immunomedics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Immunomedics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Immunomedics’ rivals have a beta of 1.48, suggesting that their average stock price is 48% more volatile than the S&P 500.
Immunomedics rivals beat Immunomedics on 8 of the 13 factors compared.
Immunomedics Company Profile
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.